ALZ Share Price Performance
SEK 0.60
-1.25 (-67.57%)
Price SEK 0.60
Share Pricen/a
Alzinova AB (publ) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ALZ Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Alzinova AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 23, 2026
- -0.17
- 100.00%
- -97.99%
- 0.7%
About ALZ
- Founded
- 2011
- Employees
- 5
- CEO
- WebsiteView website
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
